Samsrita Labs Q3 FY26 Loss Widens to ₹335.56 Lakhs on Asset Write-off
Samsrita Labs Limited reported a net loss of ₹335.56 lakhs for Q3 FY26, a significant increase from ₹4.05 lakhs in Q3 FY25, primarily due to a ₹3.26 crore write-off of intangible assets under development. The nine-month loss expanded to ₹856.72 lakhs from ₹17.25 lakhs in the previous year. The company reported no operational revenue and saw substantial increases in other expenses during the quarter.
*this image is generated using AI for illustrative purposes only.
Samsrita labs Limited reported a substantial widening of losses for the third quarter of FY26, with net loss reaching ₹335.56 lakhs compared to ₹4.05 lakhs in the corresponding quarter of the previous year. The healthcare sector company's financial performance was significantly impacted by a major asset write-off during the quarter ended December 31, 2025.
Financial Performance Overview
The company's quarterly results showed a dramatic deterioration across key metrics:
| Metric | Q3 FY26 | Q3 FY25 | Change |
|---|---|---|---|
| Net Loss | ₹335.56 lakhs | ₹4.05 lakhs | Increased significantly |
| Total Expenses | ₹335.56 lakhs | ₹4.05 lakhs | Increased substantially |
| Employee Benefits | ₹5.32 lakhs | ₹2.76 lakhs | +92.75% |
| Other Expenses | ₹330.21 lakhs | ₹1.26 lakhs | Increased substantially |
| Basic EPS | ₹(1.48) | ₹(0.03) | Declined |
Nine-Month Performance
The nine-month period ended December 31, 2025, showed similarly concerning trends:
| Parameter | 9M FY26 | 9M FY25 | Impact |
|---|---|---|---|
| Net Loss | ₹856.72 lakhs | ₹17.25 lakhs | Substantial increase |
| Total Expenses | ₹856.72 lakhs | ₹17.25 lakhs | Major escalation |
| Employee Benefits | ₹31.28 lakhs | ₹8.28 lakhs | +277.78% |
| Other Expenses | ₹825.34 lakhs | ₹8.87 lakhs | Significant rise |
| Basic EPS | ₹(4.36) | ₹(0.12) | Deteriorated |
Major Asset Write-off
The primary driver of the increased losses was a significant write-off of intangible assets under development worth ₹3,25,95,369. The company stated that this adjustment was necessitated by technological obsolescence, as the underlying patents are no longer expected to provide future economic benefits. This write-off was recognized in the Statement of Profit and Loss for the quarter and represents a substantial one-time charge affecting the company's financial performance.
Operational Metrics
Samsrita Labs reported no revenue from operations during both the current quarter and the corresponding previous period. The company's paid-up equity share capital stood at ₹2,274.97 lakhs as of December 31, 2025, compared to ₹1,480.87 lakhs in the previous year, indicating a capital increase during the period.
Consolidated Results
On a consolidated basis, the company reported a net loss of ₹293.94 lakhs for Q3 FY26, which was partially offset by a share of profit from associates and joint ventures amounting to ₹41.62 lakhs. The consolidated nine-month loss stood at ₹771.31 lakhs. The consolidated results include contributions from associate companies Krisani Biosciences Private Limited and Qrops Advisory Services Private Limited.
Regulatory Compliance
The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 6, 2026. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and have undergone limited review by statutory auditors MGR & CO, Chartered Accountants.
Historical Stock Returns for Samsrita Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.86% | +6.67% | +4.21% | -18.57% | -0.34% | -39.30% |
15
